Last updated on February 2020

A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Brief description of study

IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of IMP4297 for Maintenance Treatment

Detailed Study Description

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of IMP4297 Following First-Line Platinum-based Chemotherapy in the Monotherapy Maintenance Treatment of Subjects with International Federation of Gynecology and Obstetrics (FIGO) Stage III-IV Ovarian Cancer. Subjects with newly diagnosed III/IV high-grade serous ovarian carcinoma (HGSOC) or other histological types of ovarian cancer, fallopian tube cancer or primary peritoneal cancer carrying breast cancer susceptibility gene (BRCA) mutation who have had a complete/partial response (CR/PR) after first-line platinum-based therapy will be randomly assigned to IMP4297 or placebo at a 2:1 ratio.

Clinical Study Identifier: NCT04169997

Find a site near you

Start Over